{"entity":{"id":"nct07284758","kind":"trial","name":"A Study to Evaluate the Efficacy of Cemsidomide + Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma","aka":[],"tldr":"A phase 2 trial of Dexamethasone in multiple myeloma, run by C4 Therapeutics, Inc., now recruiting.","summary":"A Study to Evaluate the Efficacy of Cemsidomide + Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma is a phase 2 interventional study registered as NCT07284758 by C4 Therapeutics, Inc., with 100 participants planned, started 2026-02-18 and due to reach its primary completion in 2030-03. Interventions recorded: Cemsidomide, Dexamethasone. Conditions listed: Multiple Myeloma, Relapsed/Refractory Multiple Myeloma. No results are recorded here; the registry entry is the source.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT07284758","url":"https://clinicaltrials.gov/study/NCT07284758"}],"tags":["ctgov-ingest"],"related":[],"cancers":["multiple-myeloma"],"sections":[],"technologies":[],"targets":[],"drugs":["dexamethasone"],"companies":["c4-therapeutics"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT07284758","phase":"2","setting":"A Phase 2, Open-Label, Single-Arm, Multicenter Study to Evaluate the Efficacy of Cemsidomide + Dexamethasone in Subjects With Relapsed/Refractory Multiple Myeloma","sponsor":"C4 Therapeutics, Inc.","enrolled":100,"outcomes":[]},"route":"/trials/nct07284758/","neighbours":{"cancer":[{"id":"multiple-myeloma","kind":"cancer","name":"Multiple myeloma","route":"/cancers/multiple-myeloma/"}],"drug":[{"id":"dexamethasone","kind":"drug","name":"Dexamethasone","route":"/drugs/dexamethasone/"}],"company":[{"id":"c4-therapeutics","kind":"company","name":"C4 Therapeutics","route":"/companies/c4-therapeutics/"}]}}